Coverage Analysis of Tumor Biormarker Diagnostics

Biomarker testing is critical to successfully realizing personalized medicine, both through the selection of appropriate targeted therapies as well as by directing patients to relevant clinical trials.  This report examines the private payer landscape of coverage for tumor biomarker tests in lung, breast and colorectal cancer.   The report was compiled in 2018, and indications are that coverage has improved since this analysis was conducted.